Stem Cell Research & Therapy

CORRECTION

Open Access

CrossMark

Correction to: Enhanced differentiation of human pluripotent stem cells into pancreatic progenitors co-expressing PDX1 and NKX6.1

Bushra Memon[1], Manale Karam[2], Sara Al-Khawaga[1] and Essam M. Abdelalim[1]*

Correction

The original article [1] contains a number of small errors which the authors would like to clarify:

1) In Fig. 1a of the original article, FGF10 concentration should be 50 ng/ml – as correctly stated in the Methods section – instead of 100 μg/ml.
2) Also in Fig. 1a of the original article, Activin A and EGF concentrations should both be 100 ng/ml – as correctly stated in the Methods section – instead of 100 μg/ml.
3) In the Methods section under the sub-heading "**Differentiation of human pluripotent stem cells into pancreatic progenitor**", the term, '50 ng/ml hFGF10' should be omitted from the following sentence:

"At the end of stage 3, media were changed to DMEM supplemented with 1% vol/vol B27, 0.25 mM vitamin C, 50 ng/ml hFGF10, 50 ng/ml hNOGGIN, 100 ng/ml hEGF, and 10 mM nicotinamide (Sigma, USA) for 4 days of stage 4 treatment for each protocol (Fig. 1a)."

FGF10 was only added during stages 2 & 3 of differentiation as correctly depicted in Fig. 1a.

The corrected version of Fig. 1a can be viewed ahead.

* Correspondence: emohamed@hbku.edu.qa
[1]Diabetes Research Center, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar Foundation, Doha, Qatar

Author details
[1]Diabetes Research Center, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar Foundation, Doha, Qatar. [2]Cancer Research Center, Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar Foundation, Doha, Qatar.

Reference
1. Memon B, et al. Enhanced differentiation of human pluripotent stem cells into pancreatic progenitors co-expressing PDX1 and NKX6.1. Stem Cell Res Ther. 2018;9:15. https://doi.org/10.1186/s13287-017-0759-z